CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2012--
Verastem, Inc. (NASDAQ:VSTM), a biopharmaceutical company focused on
discovering and developing drugs to treat breast and other cancers by
targeting cancer stem cells, today announced that the underwriters of
its initial public offering have exercised in full their over-allotment
option for the purchase of an additional 825,000 shares of common stock
at the initial public offering price of $10.00 per share, less
underwriting discounts and commissions.
UBS Investment Bank and Leerink Swann LLC acted as joint book-running
managers for the offering. Lazard Capital Markets LLC, Oppenheimer & Co.
Inc. and Rodman & Renshaw, LLC acted as co-managers for the offering.
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on January 26, 2012.
Copies of the final prospectus relating to this offering may be obtained
by contacting UBS Investment Bank, Attention: Prospectus Department, 299
Park Avenue, New York, NY 10171, (888) 827-7275, or Leerink Swann LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor, Boston,
MA 02110, (800) 808-7525, ext. 4814.
Source: Verastem, Inc.
Verastem, Inc.
Lacy Roosevelt, 617-520-7052
lroosevelt@webershandwick.com
View printer-friendly version
